Abstract
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
Keywords: BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II
Current Medicinal Chemistry
Title: Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Volume: 19 Issue: 1
Author(s): P. Sikiric, S. Seiwerth, R. Rucman, B. Turkovic, D. S. Rokotov, L. Brcic, M. Sever, R. Klicek, B. Radic, D. Drmic, S. Ilic, D. Kolenc, V. Stambolija, Z. Zoricic, H. Vrcic and B. Sebecic
Affiliation:
Keywords: BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II
Abstract: Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
Export Options
About this article
Cite this article as:
Sikiric P., Seiwerth S., Rucman R., Turkovic B., S. Rokotov D., Brcic L., Sever M., Klicek R., Radic B., Drmic D., Ilic S., Kolenc D., Stambolija V., Zoricic Z., Vrcic H. and Sebecic B., Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157, Current Medicinal Chemistry 2012; 19 (1) . https://dx.doi.org/10.2174/092986712803414015
DOI https://dx.doi.org/10.2174/092986712803414015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Growth Differentiation Factor 5 Regulation in Bone Regeneration
Current Pharmaceutical Design Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Editorial [Hot Topic: Nitric Oxide (Guest Editor: Greg Thatcher)]
Current Topics in Medicinal Chemistry Phenotypes and Enviromental Factors: Their Influence in PCOS
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cardiology Reviews Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy 1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities
Mini-Reviews in Medicinal Chemistry C-peptide and Neuropathy in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Structural and Functional Organization of miRNAs
Current Pharmacogenomics Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design A Complete Degradation of Organophosphates by Microwave-Assisted Hydrolysis
Current Microwave Chemistry Preclinical Evaluation of Coronary Stents: Focus on Safety Issues
Current Vascular Pharmacology Blood Pressure as a Therapeutic Target in Stroke
Current Topics in Medicinal Chemistry Voltage-Gated Sodium Channels: Mutations, Channelopathies and Targets
Current Medicinal Chemistry Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy The Basic Mechanism of Hair Growth Stimulation by Adipose-derived Stem Cells and Their Secretory Factors
Current Stem Cell Research & Therapy Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology